Lessons learned from regulatory submissions involving endogenous therapeutic analyte bioanalysis.

Area of Science:

• Pharmacology
• Analytical Chemistry
• Biochemistry

Background:

• Endogenous therapeutic analytes (e.g., hormones, vitamins) are naturally occurring substances vital for bodily functions.
• Accurate quantification of these analytes is crucial during drug development.
• Distinguishing administered exogenous analytes from endogenous counterparts presents a significant bioanalytical challenge.

Purpose of the Study:

• To present real-world case examples of endogenous therapeutic analyte bioanalysis in drug development.
• To highlight common challenges and lessons learned in this specialized area of bioanalysis.
• To provide practical regulatory strategies for handling endogenous analyte bioanalysis.

Main Methods:

• Collection and presentation of case studies from drug development programs.
• Analysis of challenges encountered in distinguishing exogenous drugs from endogenous analytes.
• Review of regulatory considerations and best practices.

Main Results:

• Demonstrated difficulties in bioanalysis due to the indistinguishable nature of exogenous and endogenous analytes.
• Identified key challenges including method validation, matrix effects, and regulatory acceptance.
• Provided insights into successful strategies employed in real drug development scenarios.

Conclusions:

• Successful bioanalysis of endogenous therapeutic analytes requires careful method development and validation.
• Addressing regulatory expectations early is critical for submissions involving endogenous analytes.
• Lessons learned from case examples offer valuable guidance for future drug development projects.